It has been a few months since Zulresso (brexanolone), the new FDA-approved treatment for postpartum depression, has been available. At our clinic, we have had multiple queries regarding how to obtain treatment with Zulresso. One [...]
It seems that there is considerable variation in the estimated prevalence of suicidal ideation in pregnant and postpartum women across studies. One element that may contribute to this variation is how we assess for this [...]
Brexanolone, to be marketed by Sage Therapeutics as Zulresso, was initially approved in March 2019, as a treatment for postpartum depression. At that time, we were told that Zulresso would be available in June 2019. [...]
In our clinic, we see many women with postpartum depression. Some women know that something is wrong fairly soon after the depression sets in, and they seek help; however, far too many women present long [...]
According to recent studies, the participation of fathers in childcare nearly doubled between 1965 and 2011. Despite this growing involvement of fathers in their children’s lives, pediatric visits continue to be focused on the mother-child [...]
Over the last decade, public awareness of the mental health challenges women face has grown tremendously, and we can say with certainty that we have succeeded in putting this important topic firmly on the medical [...]
Several weeks ago, the US Preventive Services Task Force (USPSTF) issued recommendations that all pregnant and postpartum women should be evaluated in order to determine risk for depressive illness and suggests that women at increased [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Â Since that time, Sage Therapeutics [...]
Postpartum depression (PPD) is a common and complicated illness, affecting about 15% of women in the perinatal period. Recent research from the PACT consortium (Postpartum Depression: Action Toward Causes and Treatment) has sought to classify [...]
January 30, 2019 from ObGynNews  The last decade has brought appropriate attention to the high prevalence of postpartum mood and anxiety disorders, with postpartum depression (PPD) constituting the most common complication in modern obstetrics. [...]
